November 19, 2013 7:30 AM to 9:00 AMFour Seasons Hotel, 791 West Georgia Street, Vancouver, British Columbia
Format:
In Person
Does your drug plan management keep you up at night? Perhaps not, however, you may have some important questions about:
• Is private plan spending on new medicines sustainable?;
• New research cost drivers of drugs, dental and vision care;
• Measuring the value of your drug plan vs. the costs;
• Impact of high cost drugs; and
• The impact of expanded drug patent protection if enacted Comprehensive European Trade Agreement (CETA).
This CPBI breakfast session will provide an evidence-based approach to provide answers to these questions.
Brett Skinner will use available evidence to understand why BC drug costs are the lowest in the country, address the issue of sustainability of private drug plans, define the drivers that influence drug cost increases, and provide quantitative and qualitative measures of the value of investments in drug plans. This understanding will hopefully provide context to develop strategies for ensuring sustainability of BC private drug plans.
Gail Attara will describe the results of a BC Healthcare system published study examining a drug reimbursement policy called Therapeutic Substitution, which required >50,000 BC patients with acid-related diseases, primarily gastro-oesophageal reflux disease (GERD), to make a medically unnecessary switch from their prescribed proton pump inhibitor (PPI) to the cheapest available PPI. This evidence provides insight to strategies and unintended consequences of Therapeutic Substitution to reduce costs of drug plans.
*Student pricing is available to CPBI members who have student status.